An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (734 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 22.0% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: keyprotocolmultiple sclerosisrelapsingremitting
  Phrases that lowered it: participantsthe pharmacokineticspharmacokinetic20open label
• Primary purpose: other (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 15.6% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 38 (lowers risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 28937 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 109 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drugs with FDA adverse-event history: 6 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 NCT01797965 · started 2013 · scored riskier than 93% of active trials terminated
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis NCT01051349 · started 2010 · scored riskier than 99% of active trials completed
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis NCT01064401 · started 2010 · scored riskier than 42% of active trials completed
• Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis NCT00390221 · started 2008 · scored riskier than 92% of active trials completed
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis NCT00870740 · started 2009 · scored riskier than 82% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.